Program
Anti-SIRPa Monoclonal Antibody DS-1103
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Daiichi Sankyo.
Furthest: phase 2, since Jul 28, 20262 company-led studies, 2 open or runningNext primary completion: May 31, 2029 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Daiichi Sankyo | 22 open or running | phase 2since Jul 28, 2026 | Mar 1, 2023 | May 31, 2029phase 1 · NCT05765851 |
Also a collaborator on its studies: AstraZeneca.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 1, 2023First study: phase 1 study in Advanced Solid TumorFirst studyNCT05765851 · 128 planned · United States, Canada, France and more
- Jul 28, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungPhase 2 reachedNCT07739966 · 400 planned · United States, Argentina, Austria and more
Ahead
- May 31, 2029Primary completion: phase 1 study in Advanced Solid TumorNCT05765851
- Jul 31, 2030Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07739966
TargetBeta
SIRPA →read by rule
“An immunoglobulin G4 (IgG4) monoclonal antibody targeting human signal-regulatory protein alpha (SIRPa; CD172a), ”NCIt, by rule
Other programs on SIRPA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-SIRPa Monoclonal Antibody BI 770371rule | Boehringer Ingelheim | phase 2 | 4 |
| Anti-SIRPalpha Monoclonal Antibody BYON4228rule | byondis-b-v | phase 1 | 2 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07739966Carcinoma, Non-Small-Cell Lung · United States, Argentina, Austria and more | 2 | Recruiting | Jul 31, 2030 | 400 |
| NCT05765851Advanced Solid Tumor · United States, Canada, France and more | 1 | Recruiting | May 31, 2029 | 128 |
How it is read
Names in the registry
- “DS-1103a”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.